Literature DB >> 20857422

Internal pilots for observational studies.

Matthew J Gurka1, Christopher S Coffey, Kelly K Gurka.   

Abstract

Study planning often involves selecting an appropriate sample size. Power calculations require specifying an effect size and estimating "nuisance" parameters, e.g. the overall incidence of the outcome. For observational studies, an additional source of randomness must be estimated: the rate of the exposure. A poor estimate of any of these parameters will produce an erroneous sample size. Internal pilot (IP) designs reduce the risk of this error - leading to better resource utilization - by using revised estimates of the nuisance parameters at an interim stage to adjust the final sample size. In the clinical trials setting, where allocation to treatment groups is pre-determined, IP designs have been shown to achieve the targeted power without introducing substantial inflation of the type I error rate. It has not been demonstrated whether the same general conclusions hold in observational studies, where exposure-group membership cannot be controlled by the investigator. We extend the IP to observational settings. We demonstrate through simulations that implementing an IP, in which prevalence of the exposure can be re-estimated at an interim stage, helps ensure optimal power for observational research with little inflation of the type I error associated with the final data analysis.

Entities:  

Mesh:

Year:  2010        PMID: 20857422     DOI: 10.1002/bimj.201000050

Source DB:  PubMed          Journal:  Biom J        ISSN: 0323-3847            Impact factor:   2.207


  3 in total

1.  Rationale, objectives, and design of the EUTrigTreat clinical study: a prospective observational study for arrhythmia risk stratification and assessment of interrelationships among repolarization markers and genotype.

Authors:  Joachim Seegers; Marc A Vos; Panagiota Flevari; Rik Willems; Christian Sohns; Dirk Vollmann; Lars Lüthje; Dimitrios T Kremastinos; Vincent Floré; Mathias Meine; Anton Tuinenburg; Rachel C Myles; Dirk Simon; Jürgen Brockmöller; Tim Friede; Gerd Hasenfuß; Stephan E Lehnart; Markus Zabel
Journal:  Europace       Date:  2011-11-23       Impact factor: 5.214

2.  An internal pilot design for prospective cancer screening trials with unknown disease prevalence.

Authors:  John T Brinton; Brandy M Ringham; Deborah H Glueck
Journal:  Trials       Date:  2015-10-13       Impact factor: 2.279

Review 3.  Adaptive trial designs: a review of barriers and opportunities.

Authors:  John A Kairalla; Christopher S Coffey; Mitchell A Thomann; Keith E Muller
Journal:  Trials       Date:  2012-08-23       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.